Our Company
Who we are
Board of directors
Team
Stakeholders
Our programs
Pipeline
Stage of Development
Clinical Studies
Media
Contact
Our Company
Who we are
Board of directors
Team
Stakeholders
Our Programs
Pipeline
Stage of Development
Clinical Studies
Media
Contact
Press & Media
NdP - OneChain Immunotherapeutics secures €6.7M in pre-series A funding round
news
Promising therapy to treat an aggressive type of leukemia receives 2.5 million euros from the EU to reach patients
news
Autorizado un ensayo clínico único en el mundo con tecnología CAR-T para pacientes con un subtipo de Leucemia de células T
news
(Spanish) Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics
news
(Spanish) Fundación Carreras crea 'spin-off' para desarrollar terapia inmunooncológica
news
[PR] - OneChain Immunotherapeutics achieves FDA Orphan Drug designation for OC-1
news
Tweets by OneChainTX
